Publication | Closed Access

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Gastrointestinal OncologyMalignant DiseaseMedicinePathologyRadiant-4 StudySafety ResultsCancer TreatmentNeuroendocrine TumorsOncologyRadiation OncologyLung CancerCancer ResearchPhase 3